Fiche publication
Date publication
avril 2025
Journal
Gut and liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
Tous les auteurs :
Desert R, Gianonne F, Saviano A, Hoshida Y, Heikenwälder M, Nahon P, Baumert TF
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfactory. While the clinical introduction of immune checkpoint inhibitors has improved response rates and overall survival, their clinical success remains still limited. Here we provide a comprehensive review of current and emerging strategies aimed at enhancing the efficacy of immunotherapy for the treatment of HCC. Both clinical studies conducted in patients as well as studies in preclinical models have markedly advanced our understanding of resistance as well as uncovered novel approaches to overcome resistance. Recent progress is paving the way for improved efficacy and safety of novel approaches that will improve the dismal prognosis of patients with advanced HCC.
Mots clés
Humans, Carcinoma, Hepatocellular, therapy, Liver Neoplasms, therapy, Immunotherapy, methods, Immune Checkpoint Inhibitors, therapeutic use, Animals, Disease Models, Animal
Référence
Gut Liver. 2025 04 3;2(1):
